ATE431558T1 - Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb) - Google Patents
Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb)Info
- Publication number
- ATE431558T1 ATE431558T1 AT06825096T AT06825096T ATE431558T1 AT E431558 T1 ATE431558 T1 AT E431558T1 AT 06825096 T AT06825096 T AT 06825096T AT 06825096 T AT06825096 T AT 06825096T AT E431558 T1 ATE431558 T1 AT E431558T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- disease
- phosphorylated
- specific
- ratio
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 5
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 title 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 title 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 title 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 title 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
- 230000026731 phosphorylation Effects 0.000 title 1
- 238000006366 phosphorylation reaction Methods 0.000 title 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 5
- 108091054455 MAP kinase family Proteins 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000003923 Protein Kinase C Human genes 0.000 abstract 1
- 108090000315 Protein Kinase C Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/036014 WO2007043998A1 (en) | 2005-10-11 | 2005-10-11 | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
| US11/246,524 US7595167B2 (en) | 2005-10-11 | 2005-10-11 | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| PCT/US2006/022156 WO2007044094A1 (en) | 2005-10-11 | 2006-06-07 | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| PCT/US2006/037186 WO2007047029A2 (en) | 2005-10-11 | 2006-09-25 | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE431558T1 true ATE431558T1 (de) | 2009-05-15 |
Family
ID=37067652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06825096T ATE431558T1 (de) | 2005-10-11 | 2006-09-25 | Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180024146A1 (https=) |
| EP (5) | EP2322936A1 (https=) |
| JP (1) | JP4908514B2 (https=) |
| KR (2) | KR20140002073A (https=) |
| AT (1) | ATE431558T1 (https=) |
| CA (1) | CA2625300C (https=) |
| DE (1) | DE602006006855D1 (https=) |
| ES (5) | ES2412268T3 (https=) |
| TW (2) | TW201413246A (https=) |
| WO (1) | WO2007044094A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1549721B (zh) | 2001-02-27 | 2012-03-07 | 布朗歇特洛克菲勒神经科学研究所 | 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病 |
| US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| CN103961347A (zh) * | 2006-07-28 | 2014-08-06 | 布朗歇特洛克菲勒神经科学研究所 | 刺激细胞生长、突触重塑和巩固长期记忆的方法 |
| EP3332797A3 (en) | 2007-02-09 | 2018-08-01 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury |
| EP2669386A1 (en) | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of alzheimer's disease |
| WO2010014585A1 (en) | 2008-07-28 | 2010-02-04 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| BRPI0914859A2 (pt) * | 2008-08-27 | 2015-11-03 | Lundbeck & Co As H | método para diagnosticar um distúrbio afetivo, produto de programa de computador, computador, e, método para determinar uma probabilidade de que um indivíduo de teste exiba um sintoma de um distúrbio afetivo |
| US8658134B2 (en) | 2009-10-02 | 2014-02-25 | Blanchette Rockefeller Neurosciences Institute | Fibroblast growth patterns for diagnosis of Alzheimer's disease |
| JP6013184B2 (ja) * | 2009-10-02 | 2016-10-25 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化 |
| CA2835686C (en) * | 2011-05-12 | 2019-10-01 | Florin V. Chirila | Peripheral diagnostic methods for screening alzheimer's disease using beta amyloid and intercellular communication |
| EP2780316B1 (en) | 2011-11-13 | 2020-04-15 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
| KR101351978B1 (ko) * | 2012-10-30 | 2014-01-16 | 주식회사 코씨드바이오팜 | 참치 안구 파쇄물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물 |
| CA2935266C (en) * | 2014-01-03 | 2022-02-01 | Blanchette Rockefeller Neurosciences Institute | Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease |
| US11415574B2 (en) | 2017-03-31 | 2022-08-16 | NeuroDiagnostics LLC | Lymphocyte-based morphometric test for alzheimer's disease |
| WO2020237203A1 (en) * | 2019-05-23 | 2020-11-26 | Indiana University Research And Technology Corporation | Methods for objective assessment of memory, early detection of risk for alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4374316B2 (ja) * | 1993-01-25 | 2009-12-02 | 武田薬品工業株式会社 | β−アミロイドまたはその誘導体に対する抗体およびその用途 |
| US6107050A (en) | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
| US20030108956A1 (en) * | 1993-05-03 | 2003-06-12 | Alkon Daniel L. | Cell tests for Alzheimer's disease |
| US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| CN1549721B (zh) * | 2001-02-27 | 2012-03-07 | 布朗歇特洛克菲勒神经科学研究所 | 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病 |
| US6825229B2 (en) * | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| KR100574017B1 (ko) | 2003-08-11 | 2006-04-26 | 삼성전자주식회사 | 잉크젯 프린터의 잉크 카트리지 |
| US7199386B2 (en) | 2004-07-29 | 2007-04-03 | General Electric Company | System and method for detecting defects in a light-management film |
-
2006
- 2006-06-07 WO PCT/US2006/022156 patent/WO2007044094A1/en not_active Ceased
- 2006-09-25 KR KR1020137031223A patent/KR20140002073A/ko not_active Withdrawn
- 2006-09-25 DE DE602006006855T patent/DE602006006855D1/de active Active
- 2006-09-25 JP JP2008535546A patent/JP4908514B2/ja not_active Expired - Fee Related
- 2006-09-25 EP EP10011290A patent/EP2322936A1/en not_active Withdrawn
- 2006-09-25 CA CA2625300A patent/CA2625300C/en active Active
- 2006-09-25 ES ES08020258T patent/ES2412268T3/es active Active
- 2006-09-25 ES ES10011289.5T patent/ES2596881T3/es active Active
- 2006-09-25 EP EP10011288.7A patent/EP2339349B1/en active Active
- 2006-09-25 EP EP10011289.5A patent/EP2322934B1/en active Active
- 2006-09-25 EP EP10012836.2A patent/EP2317321B1/en active Active
- 2006-09-25 ES ES10012836.2T patent/ES2477284T3/es active Active
- 2006-09-25 ES ES10011288.7T patent/ES2588376T3/es active Active
- 2006-09-25 AT AT06825096T patent/ATE431558T1/de not_active IP Right Cessation
- 2006-09-25 EP EP08020258A patent/EP2031398B1/en active Active
- 2006-09-25 ES ES06825096T patent/ES2323813T3/es active Active
- 2006-10-11 TW TW102146766A patent/TW201413246A/zh unknown
- 2006-10-11 TW TW095137389A patent/TWI448688B/zh not_active IP Right Cessation
-
2008
- 2008-05-08 KR KR1020087011105A patent/KR101375552B1/ko not_active Expired - Fee Related
-
2017
- 2017-09-29 US US15/719,714 patent/US20180024146A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI448688B (zh) | 2014-08-11 |
| EP2322934A1 (en) | 2011-05-18 |
| EP2031398B1 (en) | 2013-02-13 |
| CA2625300A1 (en) | 2007-04-26 |
| EP2317321B1 (en) | 2014-04-02 |
| ES2596881T3 (es) | 2017-01-12 |
| EP2322934B1 (en) | 2016-08-31 |
| KR20140002073A (ko) | 2014-01-07 |
| ES2323813T3 (es) | 2009-07-24 |
| TW200801515A (en) | 2008-01-01 |
| EP2322936A1 (en) | 2011-05-18 |
| EP2339349A1 (en) | 2011-06-29 |
| WO2007044094A1 (en) | 2007-04-19 |
| KR101375552B1 (ko) | 2014-03-24 |
| US20180024146A1 (en) | 2018-01-25 |
| TW201413246A (zh) | 2014-04-01 |
| EP2339349B1 (en) | 2016-08-17 |
| JP2009511905A (ja) | 2009-03-19 |
| ES2412268T3 (es) | 2013-07-10 |
| EP2317321A1 (en) | 2011-05-04 |
| DE602006006855D1 (de) | 2009-06-25 |
| ES2477284T3 (es) | 2014-07-16 |
| CA2625300C (en) | 2018-01-02 |
| ES2588376T3 (es) | 2016-11-02 |
| EP2031398A1 (en) | 2009-03-04 |
| KR20080066785A (ko) | 2008-07-16 |
| JP4908514B2 (ja) | 2012-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE431558T1 (de) | Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb) | |
| De Bock et al. | Challenges for biomarker discovery in body fluids using SELDI‐TOF‐MS | |
| Bantscheff et al. | Quantitative mass spectrometry in proteomics: a critical review | |
| Ercan et al. | A validated antibody panel for the characterization of tau post-translational modifications | |
| Jantos-Siwy et al. | Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease | |
| Mischak et al. | CE‐MS in biomarker discovery, validation, and clinical application | |
| Burkhart et al. | iTRAQ protein quantification: A quality‐controlled workflow | |
| Fredolini et al. | Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection | |
| ATE491953T1 (de) | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis | |
| ATE370414T1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
| WO2003078962A3 (en) | Detection and quantification of modified proteins | |
| WO2005042761A3 (en) | Biomarkers for amyotrophic lateral sclerosis | |
| US20160003828A1 (en) | Breast-cancer determination method | |
| Michalusová et al. | Capillary electrophoretic profiling of in‐bone tryptic digests of proteins as a potential tool for the detection of inflammatory states in oral surgery | |
| DE60021369D1 (de) | Verfahren zur abschätzung eines magengeschwür-risikos | |
| US20020006627A1 (en) | Method for diagnosis of Alzheimer's disease | |
| EP4196797A1 (en) | Methods of identifying the presence and/or concentration and/or amount of proteins or proteomes | |
| Hsiao et al. | Variability assessment of 90 salivary proteins in intraday and interday samples from healthy donors by multiple reaction monitoring‐mass spectrometry | |
| Gomez-Auli et al. | Impact of cathepsin B on the interstitial fluid proteome of murine breast cancers | |
| Yang et al. | An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression | |
| JP5746978B2 (ja) | 急性心不全の診断、予知及び／又は予後用バイオマーカー及びその使用 | |
| WO2007047029A3 (en) | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) | |
| WO2006122053A3 (en) | Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor | |
| ATE354095T1 (de) | Verfahren zur detektion von prp unter verwendung ein makrozyklischen ligand | |
| May et al. | Use of whole blood for analysis of disease-associated biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |